Ezechiel J. Semengue

Yaounde, CE, Cameroon

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Brief communication: virological response and drug resistance patterns among men who have sex with men in Yaoundé-Cameroon.

Brief communication: virological response and drug resistance patterns among men who have sex with men in Yaoundé-Cameroon.

Journal: AIDS research and therapy

Published: February 18, 2026

Verification of False Reactivity in HIV Rapid Diagnostic Tests and Its Translation Into the Three Tests Algorithm in Cameroon.

Verification of False Reactivity in HIV Rapid Diagnostic Tests and Its Translation Into the Three Tests Algorithm in Cameroon.

Journal: Journal of clinical laboratory analysis

Published: February 02, 2026

Efficacy of dolutegravir-based therapy in achieving virological suppression in PLHIV in low- and middle-income countries: real-world evidence from a large clinical cohort in Cameroon.

Efficacy of dolutegravir-based therapy in achieving virological suppression in PLHIV in low- and middle-income countries: real-world evidence from a large clinical cohort in Cameroon.

Journal: BMC infectious diseases

Published: December 05, 2025

Interest in long-acting injectable ART among adolescents with perinatally acquired HIV in Cameroon: Implications for implementation in developing countries.

Interest in long-acting injectable ART among adolescents with perinatally acquired HIV in Cameroon: Implications for implementation in developing countries.

Journal: PLOS global public health

Published: November 25, 2025

Three-Year Outcomes After Genotyping-Guided Treatment Switch in HIV Patients with Virologic Failure in Cameroon: Implications for Epidemic Control in Low- and Middle-Income Countries.

Three-Year Outcomes After Genotyping-Guided Treatment Switch in HIV Patients with Virologic Failure in Cameroon: Implications for Epidemic Control in Low- and Middle-Income Countries.

Journal: Journal of global antimicrobial resistance

Published: October 14, 2025

Advancing implementation science and policy on HIV/AIDS: outcomes from the fourth edition of the Cameroon HIV operational research forum (CAM-HERO) 2024.

Advancing implementation science and policy on HIV/AIDS: outcomes from the fourth edition of the Cameroon HIV operational research forum (CAM-HERO) 2024.

Journal: The Pan African medical journal

Published: October 10, 2025

Diagnostic Concordance of Two- and Three-Gene SARS-CoV-2 Molecular Assays in Cameroon: Implications for Efficient Pandemic Response in Low- and Middle-Income Countries.

Diagnostic Concordance of Two- and Three-Gene SARS-CoV-2 Molecular Assays in Cameroon: Implications for Efficient Pandemic Response in Low- and Middle-Income Countries.

Journal: Journal of clinical laboratory analysis

Published: May 17, 2025

Acquired HIV-1 drug resistance to reverse transcriptase and protease inhibitors among people failing antiretroviral therapy in Cameroon and implications for future treatment options.

Acquired HIV-1 drug resistance to reverse transcriptase and protease inhibitors among people failing antiretroviral therapy in Cameroon and implications for future treatment options.

Journal: AIDS research and therapy

Published: March 01, 2025

Monitoring of virological response and acquired HIV-1 drug resistance among patients initiating antiretroviral therapy in the Centre Region of Cameroon.

Monitoring of virological response and acquired HIV-1 drug resistance among patients initiating antiretroviral therapy in the Centre Region of Cameroon.

Journal: The Pan African medical journal

Published: February 05, 2025

Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.

Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.

Journal: Journal of the International Association of Providers of AIDS Care

Published: December 23, 2024

Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries.

Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries.

Journal: Viruses

Published: December 01, 2024

HIV-1 cross-resistance to second-generation non-nucleoside reverse transcriptase inhibitors among individuals failing antiretroviral therapy in Cameroon: implications for the use of long-acting treatment regimens in low- and middle-income countries.

HIV-1 cross-resistance to second-generation non-nucleoside reverse transcriptase inhibitors among individuals failing antiretroviral therapy in Cameroon: implications for the use of long-acting treatment regimens in low- and middle-income countries.

Journal: JAC-antimicrobial resistance

Published: November 05, 2024

Showing 1-12 of 36

Last Updated: 09/26/2026